Project Grant R21CA280453
Award Date
9/20/23
Completion Date
8/31/25
Dollars Obligated
$402K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40292, USA
Similar Awards
The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...
The National Cancer Institute (NCI) awarded a $566,523 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Colorado-Denver. The 5-year grant, awarded on Dec 5, 2024, will fund research to identify interception targets in persistent lung pre-malignant lesions (PMLs) and determine the effects of prevention agents on persistence pathways. The research aims to develop a precision approach for lung cancer prevention by intercepting PMLs most...
The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...
This Project Grant award of $602,315 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and leverage it to screen and test new prevention agents. The key objectives are: Defining the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignancy. Validating an ex vivo precision cut lung slice approach to screening potential prevention agents...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $540,288 Project Grant to the University of Florida to research the role of bacterial-derived small molecules in improving the efficacy of immunotherapy for non-small cell lung cancer (NSCLC). The project aims to characterize a bacterial metabolite called BAC429, which has been shown to augment the anti-tumor effects of anti-PD-1 immunotherapy in preclinical models. The research will...
This $650,450 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California (USC) aims to advance the development of T cell receptor (TCR)-engineered CD4+ T cell immunotherapy for lung cancer. The key objectives of the award are to: 1) determine the mechanisms by which the novel MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer cells; 2) produce GMP-grade master cell bank and viral particles, and...
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop an innovative approach to treat lung cancer, the leading cause of cancer deaths in the U.S. The $635,248 award to Trustees of Boston University aims to create a self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BiTE) antibody. The key products and services include: Designing modified SARNA constructs encoding BiTE antibodies and...
This $230,010 project grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to unravel the drivers of metastasis in small cell lung cancer (SCLC) using human pluripotent stem cell-based models. The research strategy integrates stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to examine cell behavior in primary tumors and metastatic sites....
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded The Johns Hopkins University a $630,781 Project Grant (R01CA293906) on April 25, 2025 to develop engineered lipid nanoparticle (LNP) and microgel matrix formulations to program Th1/Th2 immune responses for cancer immunotherapy. The key objectives are to: 1) develop mRNA LNP formulations capable of eliciting dual or biased Th1/Th2 immune responses using machine learning; 2) engineer mRNA LNP-loaded microgels as an...